| Characterization and structural analysis of HIV-1 integrase conservation F Ceccherini-Silberstein, I Malet, R D'Arrigo, A Antinori, AG Marcelin, ... AIDS Rev 11 (1), 17-29, 2009 | 177 | 2009 |
| Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels MM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ... Clinical infectious diseases 58 (8), 1156-1164, 2014 | 81 | 2014 |
| Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D’Arrigo, ... Journal of Infectious Diseases 205 (4), 557-567, 2012 | 72 | 2012 |
| Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, ... Journal of antimicrobial chemotherapy 65 (11), 2305-2318, 2010 | 63 | 2010 |
| Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors F Ceccherini-Silberstein, K Van Baelen, D Armenia, M Trignetti, ... Antimicrobial agents and chemotherapy 54 (9), 3938-3948, 2010 | 57 | 2010 |
| Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group V Svicher, R D'Arrigo, C Alteri, M Andreoni, G Angarano, A Antinori, ... New Microbiologica 33 (3), 195-206, 2010 | 56 | 2010 |
| Impact of pre-therapy viral load on virological response to modern first-line HAART MM Santoro, D Armenia, C Alteri, P Flandre, A Calcagno, M Santoro, ... Antiviral therapy 18 (7), 867-876, 2013 | 48 | 2013 |
| Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA M Zaccarelli, MM Santoro, D Armenia, V Borghi, W Gennari, C Gori, ... Journal of Clinical Virology 82, 94-100, 2016 | 40 | 2016 |
| Performance evaluation of the COBAS/TaqMan HIV-1 v2. 0 in HIV-1 positive patients with low viral load: a comparative study P Paba, L Fabeni, M Ciccozzi, CF Perno, M Ciotti Journal of virological methods 173 (2), 399-402, 2011 | 40 | 2011 |
| Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group C Alteri, M Montano, R D'Arrigo, M Andreoni, G Angarano, A Antinori, ... New Microbiologica 35 (1), 17-25, 2012 | 30 | 2012 |
| HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia D Armenia, L Fabeni, C Alteri, D Di Pinto, D Di Carlo, A Bertoli, C Gori, ... Journal of Antimicrobial Chemotherapy 70 (6), 1865-1873, 2015 | 29 | 2015 |
| Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and … M Pollicita, M Surdo, F Di Santo, MF Cortese, L Fabeni, V Fedele, I Malet, ... Journal of Antimicrobial Chemotherapy 69 (9), 2412-2419, 2014 | 28 | 2014 |
| Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy L Cuypers, B Vrancken, L Fabeni, N Marascio, V Cento, VC Di Maio, ... BMC Evolutionary Biology 17, 1-10, 2017 | 27 | 2017 |
| High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance V Malagnino, R Salpini, G Maffongelli, A Battisti, L Fabeni, L Piermatteo, ... PLoS One 13 (3), e0195045, 2018 | 26 | 2018 |
| Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy MM Santoro, C Alteri, L Ronga, P Flandre, L Fabeni, F Mercurio, ... AIDS Research and Human Retroviruses 28 (10), 1285-1293, 2012 | 26 | 2012 |
| The lowest X4 Geno2Pheno false‐positive rate is associated with greater CD4 depletion in HIV‐1 infected patients MM Santoro, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Svicher, ... Clinical Microbiology and Infection 18 (8), E289-E298, 2012 | 26 | 2012 |
| Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients F Ceccherini-Silberstein, I Malet, L Fabeni, V Svicher, C Gori, S Dimonte, ... Antiviral Therapy 12, S6-S6, 2007 | 26 | 2007 |
| Comparative evaluation of subtyping tools for surveillance of newly emerging HIV-1 strains L Fabeni, G Berno, J Fokam, A Bertoli, C Alteri, C Gori, F Forbici, D Takou, ... Journal of Clinical Microbiology 55 (9), 2827-2837, 2017 | 25 | 2017 |
| HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania F Vairo, E Nicastri, G Liuzzi, Z Chaula, B Nguhuni, N Bevilacqua, F Forbici, ... BMC infectious diseases 13, 1-8, 2013 | 25 | 2013 |
| Recent transmission clustering of HIV-1 C and CRF17_BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy L Fabeni, C Alteri, N Orchi, C Gori, A Bertoli, F Forbici, F Montella, ... PLoS One 10 (8), e0135325, 2015 | 24 | 2015 |
Francesca Ceccherini SilbersteinRicercatore Università di Roma Tor VergataBestätigte E-Mail-Adresse bei med.uniroma2.it
